在全球抗击艾滋病的大背景下，新的希望正在闪现。2025年，美国预计将上市全球首款半年一次注射的HIV长效预防药物——Lenacapavir（来那卡帕韦），这一消息无疑为在校学生、留学生及高危人群带来了新的选择和希望，也让人们开始深思在充满挑战的留学环 ...

新一轮的抗HIV药物革命即将来临！万众期待的Lenacapavir（来那卡帕韦）作为全球首款每年两针的长效HIV预防药物，有望在2025年中至年底正式上市。那么，这一重磅消息究竟有何意义？让我们一同拆解这一医疗界的里程碑事件。

A modelling study shows that lenacapavir could end Aids in South Africa by 2032 – but only if between two and four million ...

本文聚焦 HIV-1 衣壳抑制剂 Lenacapavir（LEN），通过体外和细胞实验，发现其能破坏病毒核心完整性，却稳定衣壳晶格，抑制病毒核输入，与 PF-3450074（PF74）作用机制不同，为抗 HIV-1 治疗提供新见解。 研究背景 HIV-1（人类免疫缺陷病毒 1 型）作为一种逆转录病毒 ...

吉利德科学（Gilead Sciences）公司日前公布了两种每年一次的lenacapavir配方，作为暴露前预防（PrEP）疗法，在1期临床试验中的积极结果。数据支持每年 ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

有不少人认为，得益于给药更加方便，lenacapavir将在HIV预防领域占据主导地位，影响力有望进一步扩大。但也有业内人士指出，该药的副作用不容忽视，现在下定论为时尚早。 在GSK企业发展总裁David Redfern看来，在针对lenacapavir的Purpose ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – – Also at CROI: New PURPOSE 1 Data Showcasing ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor ...